The purpose of this article is to increase awareness of osteoporosis incidence in patients with hip fracture among providers and allied health professionals, to increase osteoporosis recognition and treatment in post hip-fracture patients, and to provide guidance on how to improve continuity of care and collaboration between members of the multidisciplinary healthcare team.
Recent evidence from the literature is reviewed to identify effective management strategies for post low-energy trauma hip-fracture patients and prevention of future osteoporotic fracture, regardless of osteoporosis diagnosis prior to the initial fracture.
Despite the availability of accurate screening technologies and highly efficacious antiosteoporosis medications, implementation of these measures for low-energy trauma hip-fracture patients remains critically low. This is because of a number of factors including hesitancy to integrate care across specialty lines, lack of reliable referral systems, and resistance to change. There is also a lack of recognition of the connection between low-energy trauma hip fracture and osteoporosis by many healthcare professionals.
All members of the multidisciplinary care team are called to action to adopt osteoporosis evaluation and treatment strategies that research has shown to be effective on a larger scale in the post hip-fracture setting.
1 Yale University School of Nursing, New Haven, Connecticut,
bProfessor, Director of Adult-Gerontological, Family, and Women's Health Nurse Practitioner Primary Care Specialty
Received 25 April 2012; accepted 10 October 2012
Correspondence Ivy M. Alexander, PhD, APRN, ANP-BC, FAAN, PO Box 9740, 100 Church Street South, Suite #200, New Haven, Connecticut 06536-0740. Tel: 203-737-2359; Fax: 203-785-6455; E-mail: firstname.lastname@example.org
To obtain CE credit for this activity, go to http://www.aanp.org and click on the CE Center. Locate the listing for this article and complete the post-test. Follow the instructions to print your CE certificate.
Disclosures One of the authors (I.A.) has served as a consultant and speaker for Amgen, manufacturer of denosumab. No other relationship exists between any of the authors and any commercial entity of product mentioned in this article that might represent a conflict of interest. There was no solicitation of the authors by any commercial entity to submit the manuscript for publication.